COVID19N-REAAD Anti-SARS-CoV-2 Qualitative Nucleocapsid Protein IgG ELISA


COVID19N-REAAD™ Anti-SARS-CoV-2 Nucleocapsid Protein IgG ELISA (Coronavirus Disease 2019– REcombinant Antigen-Antibody Detection) is an enzyme–linked immunosorbent assay intended for qualitative detection of SARS-CoV-2 IgG antibodies in human serum and plasma. The assay is for research use only and not intended for diagnostic procedures.

COVID19N-REAAD Anti-SARS-CoV-2 Qualitative Nucleocapsid Protein IgG ELISA Assay Kit

COVID19N-REAAD Anti-SARS-CoV-2 Qualitative Nucleocapsid Protein IgG ELISA was developed and manufactured by Restalyst

Size: 1×96 wells
Incubation Time
: 1.5 Hours
Sample Type: Serum or Plasma
Species Sample: Human
Sample Size: 2 µL
Alternative Names: Serology, Coronavirus, COVID-19, Corona, Serological, COVID Antibody
For Research Use Only and not for use in diagnostic procedures.

Controls Included

Assay Principle

Recombinant SARS-CoV-2 nucleocapsid proteins are bound onto the microwells. Diluted serum specimens are added to antigen-coated wells and incubated. After incubation and washing, human antibodies targeting SARS-CoV-2 antigens remain bound to the well surface. Secondary antibody conjugated to horseradish peroxidase (HRP) targeting human IgG is then added to each well. After incubation, the ELISA wells are washed once again before a tetramethylbenzidine (TMB) substrate is added. As the assay determination is based on enzymatic reaction, the reaction can be stopped by the addition of 1N H2SO4, which will turn the blue coloration to yellow. The wells can then be read on any suitable spectrophotometer or microwell ELISA plate reader. It is always recommended to read the wells at 450 nm against a 620-630 nm reference filter to eliminate any possible causes of interference.

Products Related to COVID-19 Nucleocapsid IgG Quantitative ELISA Assay Kit

Coronavirus COVID-19 IgG ELISA Assay Kit
Coronavirus COVID-19 IgM ELISA Assay Kit
Anti-SARS-CoV-2 S1 (RBD) IgG ELISA Assay

Additional Information

Assay Background

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in December 2019, and has since spread globally, resulting in the ongoing pandemic. Majority of the cases result in mild symptoms, however some progress to pneumonia and multi-organ failure. The overall mortality rate for this disease was up to 4.6% (ranging from 0.2% to 15% according to age group and other health problems).

SARS-CoV-2 is predominantly transmitted by droplet infection via coughing or sneezing and through close contact with infected persons. The incubation time of SARS-CoV-2 is three to seven, maximally 14 days. It has been reported that PCR-confirmed SARS-CoV-2 positive persons may seroconvert and develop antibodies against SARS-CoV-2 antigens anywhere from 6-21days after the onset of clinical symptoms. The specific and reliable detection of human IgG antibodies to SARS-CoV-2 remains a key method to monitor infections, to effect contact tracing, and for serosurveillance.

COVID19N-REAAD™ detects IgG antibodies against SARS-CoV-2 nucleocapsid protein and is used to determine if an individual has been exposed to SARS-CoV-2 with other testing methods.


Product Manual

Product Citations